ライフサイエンスコーパス: HIV seroconversion

1 en prevalent or incident HSV-2 infection and HIV seroconversion.

2 n were reconstructed from estimated dates of HIV seroconversion.

3 in which gel users are closely monitored for HIV seroconversion.

4 imilar to the longitudinal estimate based on HIV seroconversion.

5 tic cell density, which potentially mediates HIV seroconversion.

6 d to estimate adjusted odds ratios (aORs) of HIV seroconversion.

7 ase of suicidal attempt in a woman following HIV seroconversion.

8 27, p<0.0001) in the past 6 months predicted HIV seroconversion.

9 The primary outcome was time to HIV seroconversion.

10 sessed how this risk changes with time since HIV seroconversion.

11 per patient were done retrospectively after HIV seroconversion.

12 Documentation of recent HIV seroconversion.

13 nce estimate based on prospectively observed HIV seroconversions.

14 At 10 years since HIV seroconversion, 283 individuals had LTNP, of whom 20

15 and any detectable HPV at the visit prior to HIV seroconversion (adjusted odds ratio, 1.02; 95% confi

16 sition was not significantly associated with HIV seroconversion, after adjustment for sexual behavior

17 lts suggest an independent increased risk of HIV seroconversion among HPV-positive men.

18 HBV seroconversion predicted subsequent HIV seroconversion among male IDUs (relative incidence [

19 was observed in the first 5 years following HIV seroconversion among those infected sexually, though

20 ed long-term progression-free survival after HIV seroconversion and aimed to identify factors associa

21 HPV clearance was associated with subsequent HIV seroconversion and also with increased epidermal den

22 ty to reach persons who are at high risk for HIV seroconversion and provide them with evaluation, tre

23 lled in the present study within 6 months of HIV seroconversion and self-selected whether to initiate

24 use of BED-CEIA for the detection of recent HIV seroconversion and the calculation of incidence esti

25 of acute HIV infection, (2) documentation of HIV seroconversion, and (3) detection of recent HIV infe

26 HCV RNA load stabilized at 4 years after HIV seroconversion, and this point was used for analysis

27 clearance was significantly associated with HIV seroconversion (aOR, 3.25 [95% confidence interval {

28 al among HIV-positive men 5 to 6 years after HIV seroconversion, but not at 12 to 18 months, and the

29 IV status and TB was estimated by time since HIV seroconversion, calendar period, and age.

30 Samples from 213 women who experienced HIV seroconversion (cases) during a longitudinal study i

31 ected injection drug users (IDUs) with known HIV seroconversion dates from four cohort studies were p

32 portance of assessing the genetic linkage of HIV seroconversion events in HIV prevention studies invo

33 inguish recent human immunodeficiency virus (HIV) seroconversion from long-term infections.

34 Dates of HIV seroconversion had been estimated for all patients,

35 l counts after human immunodeficiency virus (HIV) seroconversion have decreased over calendar time am

36 ated risks for human immunodeficiency virus (HIV) seroconversion; however, others have reported highe

37 um specimens were selected with reference to HIV seroconversion: (i) more than 2 years prior, (ii) le

38 ulatory care clinics in Italy, with observed HIV seroconversion in 1980-1988.

39 bserved a trend toward lower d(N)/d(S) after HIV seroconversion in 7 of 10 subjects and lower d(N)/d(

40 At HIV seroconversion in 8 of 15 patients, a 30-bp deletion

41 SETTING, AND POPULATION: Mortality following HIV seroconversion in a large multinational collaboratio

42 ith the MAA to the annual incidence based on HIV seroconversion in a longitudinal cohort.

43 dy was conducted to examine risk factors for HIV seroconversion in homosexual men who became infected

44 entify a trend of lower CD4 counts following HIV seroconversion in Italy and suggest indirectly that

45 Independent predictors of HIV seroconversion in multivariable pooled logistic regr

46 The main outcome of this study was HIV seroconversion in the intent-to-treat population as

47 We observed 1619 HIV seroconversions in 17 016 individuals, over 60 349 p

48 The odds of HIV seroconversion increased with increasing number of H

49 nd the risk of human immunodeficiency virus (HIV) seroconversion is unclear, and the genital cellular

50 th Poisson regression to model predictors of HIV seroconversion, models that included measures of NEP

51 Eight HIV seroconversions occurred overall, with four document

52 tion was 17.2 cases per 100 person years; no HIV seroconversions occurred.

53 ction was detected in 85 percent of men with HIV seroconversion on the basis of the presence of E2 an

54 of 0.45 logs, increasing by 0.60 logs after HIV seroconversion (P < .0001), by 0.12 logs each subseq

55 igher HIV RNA levels in the first year after HIV seroconversion (P=.88) or faster rates of increase o

56 reening or confirmatory tests using an acute HIV seroconversion panel.

57 ase chain reaction (RT-PCR) assays in 3 of 5 HIV seroconversion panels.

58 The HIV seroconversion rate was 6.4 (95% CI: 1.3-18.7) per 1

59 In contrast, HIV seroconversion rates varied little from the overall

60 ces by geographical origin (GO) in time from HIV seroconversion (SC) to AIDS, death, and initiation o

61 thm for recent human immunodeficiency virus (HIV) seroconversion (STARHS) distinguishes between recen

62 ing a serologic testing algorithm for recent HIV seroconversion that uses both a sensitive and a less

63 tients was also evaluated 5 to 6 years after HIV seroconversion (the late visit).

64 panels from 155 persons identified prior to HIV seroconversion to assess antibody-based methods for

65 In a cohort study, annual incidence based on HIV seroconversion was 1.04% (95% CI, .70%-1.55%).

66 2 weeks and 6 months after (early treatment) HIV seroconversion was associated with improvements in t

67 HIV seroconversion was associated with raised genital in

68 the loss of GBV-C RNA by 5 to 6 years after HIV seroconversion was associated with the poorest progn

69 HIV incidence based on HIV seroconversion was calculated as number of events/10

70 nalyzed samples were from the visit in which HIV seroconversion was detected and the visit preceding

71 Using stored serum, the precise timing of HIV seroconversion was determined and the early effects

72 GBV-C status 12 to 18 months after HIV seroconversion was not significantly associated with

73 en early after human immunodeficiency virus (HIV) seroconversion was investigated in a cohort of 96 m

74 For the primary outcome (time to HIV seroconversion) we analysed 3011 women in the Carrag

75 er, men without GBV-C RNA 5 to 6 years after HIV seroconversion were 2.78 times as likely to die as m

76 In addition, no HIV seroconversions were detected among prison inmates.

77 No other HIV seroconversions were identified during the study.

78 Of these, 145 HIV seroconversions were observed, resulting in a weight